WallStSmart
MAZE

Maze Therapeutics, Inc. Common Stock

NASDAQ: MAZE · HEALTHCARE · BIOTECHNOLOGY

$25.68
-1.04% today

Updated 2026-04-29

Market cap
$1.42B
P/E ratio
P/S ratio
501.65x
EPS (TTM)
$-3.05
Dividend yield
52W range
$8 – $54
Volume
0.9M

Maze Therapeutics, Inc. Common Stock (MAZE) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
1 of 5
Last 5 quarters
Avg EPS surprise
-27.1%
Last 4 quarters
Revenue YoY growth
Most recent quarter
EPS YoY growth
+96.5%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-13.3%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
-35.3%
2026-03-25
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-25$-0.65+5.7%$49.00$31.71-35.3%
2025-11-06$-0.66-6.5%$30.27$28.60-5.5%
2025-08-12$-0.77-24.2%$13.47$13.60+1.0%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.69$-0.65+5.7%
2025-09-30$-0.62$-0.66-6.5%
2025-06-30$-0.62$-0.77-24.2%
2025-03-31$-0.63$-1.15-83.6%
2024-12-31$0.45$-18.32-4171.1%

Frequently asked questions

Has Maze Therapeutics, Inc. Common Stock beaten earnings estimates?
Maze Therapeutics, Inc. Common Stock has beaten Wall Street EPS estimates in 1 of its last 5 quarterly reports, with an average EPS surprise of -27.1% over the last 4 quarters.
How does MAZE stock react to earnings?
MAZE stock has moved an average of -13.3% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.